JP2006528949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006528949A5 JP2006528949A5 JP2006529827A JP2006529827A JP2006528949A5 JP 2006528949 A5 JP2006528949 A5 JP 2006528949A5 JP 2006529827 A JP2006529827 A JP 2006529827A JP 2006529827 A JP2006529827 A JP 2006529827A JP 2006528949 A5 JP2006528949 A5 JP 2006528949A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- agent
- patients
- therapeutic agent
- valsartan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 4
- 229960004699 valsartan Drugs 0.000 claims 4
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47113703P | 2003-05-16 | 2003-05-16 | |
| US60/471,137 | 2003-05-16 | ||
| PCT/EP2004/005204 WO2004101535A1 (en) | 2003-05-16 | 2004-05-14 | Pharmaceutical composition comprising valsartan |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006528949A JP2006528949A (ja) | 2006-12-28 |
| JP2006528949A5 true JP2006528949A5 (enExample) | 2007-06-28 |
| JP4783733B2 JP4783733B2 (ja) | 2011-09-28 |
Family
ID=33452429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006529827A Expired - Fee Related JP4783733B2 (ja) | 2003-05-16 | 2004-05-14 | バルサルタンを含む医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070054947A1 (enExample) |
| EP (1) | EP1631556A1 (enExample) |
| JP (1) | JP4783733B2 (enExample) |
| CN (1) | CN1816533A (enExample) |
| AU (2) | AU2004238546A1 (enExample) |
| BR (1) | BRPI0410374A (enExample) |
| CA (1) | CA2525665A1 (enExample) |
| MX (1) | MXPA05012299A (enExample) |
| TW (1) | TW200509909A (enExample) |
| WO (1) | WO2004101535A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080261958A1 (en) * | 2005-11-08 | 2008-10-23 | Randy Lee Webb | Combination of Organic Compounds |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| EP2638013A4 (en) | 2010-11-12 | 2014-03-26 | Hetero Research Foundation | NEW POLYMORPHS OF CALCIUM PIVASTATIN |
| JPWO2013147137A1 (ja) * | 2012-03-30 | 2015-12-14 | 味の素株式会社 | 心不全の治療剤 |
| PL2887961T3 (pl) | 2012-08-24 | 2021-11-08 | Novartis Ag | Inhibitory nep do leczenia chorób charakteryzujących się powiększeniem lub przebudową przedsionka |
| WO2015028941A1 (en) * | 2013-08-26 | 2015-03-05 | Novartis Ag | New use |
| WO2016037552A1 (zh) * | 2014-09-09 | 2016-03-17 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi复合物及其制备方法和应用 |
| JP7470647B2 (ja) * | 2018-06-14 | 2024-04-18 | アストラゼネカ・ユーケイ・リミテッド | ジヒドロピリジン型カルシウムチャネル遮断薬医薬組成物を用いて血圧を低下させるための方法 |
| AU2019287551A1 (en) * | 2018-06-14 | 2021-01-28 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition |
| CN115317478B (zh) * | 2022-08-26 | 2023-05-02 | 宁波大学 | 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6201002B1 (en) * | 1997-01-10 | 2001-03-13 | Merck & Co., Inc. | Method for reducing mortality with an angiotensin II antagonist |
| ES2552639T3 (es) * | 1998-07-10 | 2015-12-01 | Novartis Pharma Ag | Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos |
| US6204281B1 (en) * | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
| CA2360305A1 (en) * | 1999-02-09 | 2000-08-17 | Bristol-Myers Squibb Company | Lactam inhibitors of fxa and method |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| US6544981B2 (en) * | 2000-06-09 | 2003-04-08 | Bristol-Myers Squibb Company | Lactam inhibitors of factor Xa and method |
| PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
| US6642252B2 (en) * | 2000-11-07 | 2003-11-04 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| WO2002053161A1 (en) * | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| US6395782B1 (en) * | 2001-03-02 | 2002-05-28 | Wisconsin Alumni Research Foundation | Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid |
| CA2448306A1 (en) * | 2001-05-30 | 2002-12-05 | Alteon Inc. | Method for treating fibrotic diseases or other indications |
| CA2463758A1 (en) * | 2001-10-18 | 2003-05-01 | Novartis Ag | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
-
2004
- 2004-05-14 TW TW093113753A patent/TW200509909A/zh unknown
- 2004-05-14 CN CNA2004800186113A patent/CN1816533A/zh active Pending
- 2004-05-14 WO PCT/EP2004/005204 patent/WO2004101535A1/en not_active Ceased
- 2004-05-14 AU AU2004238546A patent/AU2004238546A1/en not_active Abandoned
- 2004-05-14 MX MXPA05012299A patent/MXPA05012299A/es unknown
- 2004-05-14 EP EP04732990A patent/EP1631556A1/en not_active Withdrawn
- 2004-05-14 JP JP2006529827A patent/JP4783733B2/ja not_active Expired - Fee Related
- 2004-05-14 US US10/556,260 patent/US20070054947A1/en not_active Abandoned
- 2004-05-14 CA CA002525665A patent/CA2525665A1/en not_active Abandoned
- 2004-05-14 BR BRPI0410374-2A patent/BRPI0410374A/pt not_active IP Right Cessation
-
2008
- 2008-11-20 AU AU2008246267A patent/AU2008246267B2/en not_active Ceased
- 2008-12-22 US US12/341,669 patent/US20090105322A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512406A5 (enExample) | ||
| HUT72313A (en) | Pharmaceutical compositions for treating menstrual symptoms and process for their preparation | |
| JP3018160B2 (ja) | 月経困難症及び／又は月経前症候群の軽減用薬剤 | |
| US9034909B2 (en) | Use of organic compound for the treatment of Noonan Syndrome | |
| JP2006528949A5 (enExample) | ||
| ES2671926T3 (es) | Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico | |
| US20100168238A1 (en) | Pharmaceutical composition containing phloroglucinol and paracetamol | |
| EP4360631A1 (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| TW200911247A (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament for use in the treatment of motor disorders related to parkinson's disease | |
| RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона | |
| JPH02138123A (ja) | 心不全治療用医薬組成物 | |
| CZ79593A3 (en) | Antitussive preparation | |
| JP2010163426A (ja) | ホスホジエステラーゼ５阻害剤とアルギニンを含有する医薬組成物 | |
| JPS6058726B2 (ja) | プリン誘導体を有効成分として含有する抗アレルギ−，鎮痛，鎮静剤 | |
| KR100379155B1 (ko) | 새로운 진통제 조성물 | |
| EP3790550A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure | |
| US3073744A (en) | Therapeutic compositions against virus diseases | |
| Upadhyay et al. | Studies on Formulation and optimization of Gastro Retentive multi-Particulates of Glibenclamide and Metformin hydrochloride for the treatment of Type II Diabetes mellitus using Gelucire: A Review | |
| JP2621382B2 (ja) | 尿酸排泄剤 | |
| JPS6116A (ja) | 有機化合物に関する改良 | |
| JP3254712B2 (ja) | 医薬組成物 | |
| JPH05262747A (ja) | 潰瘍性大腸炎治療剤 | |
| WO2024230943A1 (en) | Linaprazan glurate for treating gastroesophageal reflux disease (gerd) | |
| CN1374083A (zh) | 抗感冒的复方药物组合物 | |
| US20060063813A1 (en) | Organic compounds |